A case report highlights a 51-year-old man with stage IV non-small cell lung cancer and brain metastasis who received whole ...

Grade 3-5 adverse events were comparable between both treatment groups. Evidence Rating Level: 1 (Excellent) Study Rundown: ...

In the last decade, immunotherapy agents changed the treatment landscape for Non-Small Cell Lung Cancer (NSCLC)."BUFFALO, NY ...

The FDA has implemented a partial hold on a phase 3 non-small cell lung cancer trial run by BioNTech and OncoC4 after seeing ...

The following is a summary of “Association of mutation profiles with metastasis in patients with non-small cell lung cancer,” ...

Frankie Wilson was only 5 years old when her father, Dan, a non-smoker, was diagnosed with Stage IV non-small cell lung ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

Experts at CHEST 2024 highlighted significant racial disparities in lung cancer screening, treatment, and outcomes, ...

In a recent phase 3 trial, SBRT led to similar tumor control and survival outcomes compared with hypofractionated ...

Novocure announced on Tuesday that the FDA treated its Optune Lua wearable device for treating metastatic non-small cell lung ...